ERCC1 Expression As a Predictive Marker of Cervical Cancer Treated with Cisplatin-based Chemoradiation

被引：1
|
作者：
Muallem, Mustafa Zelal [1 ]
Marnitz, Simone [3 ]
Richter, Rolf [1 ]
Koehler, Christhardt [4 ]
Sehouli, Jalid [1 ]
Arsenic, Ruza [2 ]
机构：
[1] Charite, Virchow Campus Clin, Dept Gynecol & Obstet, D-13353 Berlin, Germany
[2] Charite, Virchow Campus Clin, Inst Pathol, D-13353 Berlin, Germany
[3] Charite, Dept Radiooncol, D-13353 Berlin, Germany
[4] Charite, Dept Gynecol & Obstet, D-13353 Berlin, Germany
来源：
ANTICANCER RESEARCH | 2014年 / 34卷 / 1A期
关键词：
ERCC1; protein; cervical cancer; chemoradiation; cisplatin; immunohistochemistry staining; NUCLEOTIDE EXCISION-REPAIR; SQUAMOUS-CELL CARCINOMA; ENDONUCLEASE ERCC1-XPF; MAMMALIAN-CELLS; SURVIVAL; RECOMBINATION; THERAPY; HEAD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: The purpose of the present study was to evaluate the correlation between repair cross-complementing group-1 (ERCC1) status and the outcome of platin-based chemoradiation of locally advanced cervical cancer. Patients and Methods: Tumor specimens from 112 patients with locally advanced cervical cancer were evaluated for ERCC1 expression. The outcome of these patients was retrospectively assessed in correlation with ERCC1 expression. Results: Increased expression of ERCC1 correlates with a better prognosis of cervical cancer. The 2-year overall survival was 68.6% in the group with low H-score for ERCC-1 and gradually increased in the intermediate and high H-score groups to 71.7% and 90.7%, respectively. Conclusion: The present study did not confirm the correlation of low levels of ERCC1 expression with unfavorable outcomes of patients with locally advanced cervical cancer treated with platin-based radiochemotherapy.
引用
收藏
页码：401 / 406
页数：6
相关论文
共 50 条
  • [1] ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
    H J Jun
    M J Ahn
    H S Kim
    S Y Yi
    J Han
    S K Lee
    Y C Ahn
    H-S Jeong
    Y-I Son
    J-H Baek
    K Park
    British Journal of Cancer, 2008, 99 : 167 - 172
  • [2] ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
    Jun, H. J.
    Ahn, M. J.
    Kim, H. S.
    Yi, S. Y.
    Han, J.
    Lee, S. K.
    Ahn, Y. C.
    Jeong, H-S
    Son, Y-I
    Baek, J-H
    Park, K.
    BRITISH JOURNAL OF CANCER, 2008, 99 (01) : 167 - 172
  • [3] Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation
    Ciaparrone, Marco
    Caspiani, Orietta
    Bicciolo, Giulio
    Signorelli, Diego
    Simonelli, Ilaria
    de Campora, Luca
    Mazzarella, Giorgio
    Mecozzi, Antonella
    Pianelli, Curzio
    Camaioni, Angelo
    Catalano, Piera
    Pasqualetti, Patrizio
    Fabiano, Alfredo
    Radici, Marco
    Marmiroli, Luca
    Corsi, Domenico Cristiano
    ONCOLOGY, 2015, 89 (04) : 227 - 234
  • [4] Clinical significance of ERCC1 expression in advanced squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
    Jun, H.
    Ahn, M.
    Kim, H.
    Park, B.
    Han, J.
    Ahn, Y.
    Jeong, H.
    Son, Y.
    Baek, J.
    Park, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    Sara De Dosso
    Elena Zanellato
    Martina Nucifora
    Renzo Boldorini
    Angelica Sonzogni
    Roberto Biffi
    Nicola Fazio
    Eraldo Bucci
    Ottavio Beretta
    Stefano Crippa
    Piercarlo Saletti
    Milo Frattini
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 159 - 165
  • [6] Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    Bellmunt, J.
    Paz-Ares, L.
    Cuello, M.
    Cecere, F. L.
    Albiol, S.
    Guillem, V.
    Gallardo, E.
    Carles, J.
    Mendez, P.
    de la Cruz, J. J.
    Taron, M.
    Rosell, R.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2007, 18 (03) : 522 - 528
  • [7] Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer
    Kawashima, Atsunari
    Takayama, Hitoshi
    Kawamura, Norihiko
    Doi, Noriteru
    Sato, Mototaka
    Hatano, Koji
    Nagahara, Akira
    Uemura, Motohide
    Nakai, Yasutomo
    Nishimura, Kensaku
    Miyoshi, Susumu
    Kawano, Kiyoshi
    Nishimura, Kazuo
    Nonomura, Norio
    Tsujimura, Akira
    ONCOLOGY LETTERS, 2012, 4 (01) : 15 - 21
  • [8] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    De Dosso, Sara
    Zanellato, Elena
    Nucifora, Martina
    Boldorini, Renzo
    Sonzogni, Angelica
    Biffi, Roberto
    Fazio, Nicola
    Bucci, Eraldo
    Beretta, Ottavio
    Crippa, Stefano
    Saletti, Piercarlo
    Frattini, Milo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 159 - 165
  • [9] ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells
    Britten, RA
    Liu, D
    Tessier, A
    Hutchison, MJ
    Murray, D
    INTERNATIONAL JOURNAL OF CANCER, 2000, 89 (05) : 453 - 457
  • [10] Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy
    Huang, Pei-Yu
    Li, Yan
    Mai, Hai-Qiang
    Luo, Rong-Zhen
    Cai, Yu-Chen
    Zhang, Li
    ORAL ONCOLOGY, 2012, 48 (10) : 964 - 968
12345